NICE recommends Novartis’ Mayzent on the heels of SMC approval
Drug is licensed for secondary progressive multiple sclerosis with active disease
Read More
Tag: SPMS
NICE rejects Novartis’ Mayzent for secondary progressive MS
NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active disease
Read More
Novartis files MS drug siponimod in EU and US
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
Read More
Landmark MS trial launches in UK
The biggest ever trial for secondary progressive multiple sclerosis (SPMS) has kicked off in the UK at around 30 sites in England, Scotland, Wales, Northern Ireland and Eire.
Read More
US, EU filings imminent for Novartis’ MS therapy siponimod
Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the US.
Read More
Novartis’ siponimod hits targets in MS trial
Novartis has unveiled further findings from a late-stage trial of its experimental multiple sclerosis drug BAF312 (siponimod), showing that the drug cut the risk of disability progression in adults with secondary progressive forms of the disease.
Read More
Novartis’ MS drug hits primary PhIII target
Novartis’ experimental multiple sclerosis drug siponimod has hit its key target in a late-stage trial, raising hopes for a new treatment option for patients.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
